prednisone has been researched along with Sarcopenia in 10 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
Sarcopenia: Progressive decline in muscle mass due to aging which results in decreased functional capacity of muscles.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sarcopenia is known to be related to an increased risk of chemotherapy toxicity and to a poor prognosis in patients with malignancy." | 5.43 | Prognostic impact of sarcopenia in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. ( Go, SI; Kang, MH; Kim, HG; Kim, RB; Kim, Y; Lee, GW; Lee, HR; Lee, SI; Park, MJ; Song, HN, 2016) |
| " We evaluated the association of sarcopenia with febrile neutropenia hospitalization, treatment-related mortality, and ability to complete standard number of cycles in a retrospective cohort of United States veterans diagnosed with DLBCL between 1998 and 2008 and treated with cyclophosphamide, doxorubicin, vincristine, and prednisone, with or without rituximab." | 3.83 | Impact of sarcopenia on treatment tolerance in United States veterans with diffuse large B-cell lymphoma treated with CHOP-based chemotherapy. ( Carson, KR; Ganti, A; Liu, W; Luo, S; Lynch, RC; O'Brian, K; Riedell, P; Sanfilippo, KM; Xiao, DY, 2016) |
| "Sarcopenia is an independent prognostic factor in male patients with DLBCL." | 2.80 | Sarcopenia is an independent prognostic factor in male patients with diffuse large B-cell lymphoma. ( Goto, N; Hara, T; Kanemura, N; Kitagawa, J; Kito, Y; Matsumoto, T; Miyazaki, T; Nakamura, H; Nakamura, N; Ninomiya, S; Shibata, Y; Shimizu, M; Shiraki, M; Takeuchi, T; Tsurumi, H, 2015) |
| "Sarcopenia is significantly more common in patients with RA compared with controls using the EWGSOP2 criteria." | 1.72 | Prevalence of sarcopenia in patients with rheumatoid arthritis using the revised EWGSOP2 and the FNIH definition. ( Armbrecht, G; Borucki, D; Buehring, B; Buttgereit, F; Detzer, C; Dietzel, R; Schaumburg, D; Wiegmann, S; Zeiner, KN, 2022) |
| "Sarcopenia is known to be associated with poor clinical outcome in patients with diffuse large B-cell lymphoma (DLBCL)." | 1.46 | A comparison of pectoralis versus lumbar skeletal muscle indices for defining sarcopenia in diffuse large B-cell lymphoma - two are better than one. ( Go, SI; Kang, JH; Kang, MH; Kim, HG; Kim, HR; Lee, GW; Park, MJ; Song, HN, 2017) |
| "Sarcopenia is known to be related to an increased risk of chemotherapy toxicity and to a poor prognosis in patients with malignancy." | 1.43 | Prognostic impact of sarcopenia in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. ( Go, SI; Kang, MH; Kim, HG; Kim, RB; Kim, Y; Lee, GW; Lee, HR; Lee, SI; Park, MJ; Song, HN, 2016) |
| "Sarcopenia is a relevant and predictive factor in elderly patients with DLBCL treated with rituximab plus chemotherapy." | 1.40 | Sarcopenia is an independent prognostic factor in elderly patients with diffuse large B-cell lymphoma treated with immunochemotherapy. ( Clatot, F; Jardin, F; Kraut-Tauzia, J; Lanic, H; Leprêtre, S; Mareschal, S; Modzelewski, R; Picquenot, JM; Stamatoullas, A; Tilly, H, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 3 (30.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dietzel, R | 1 |
| Wiegmann, S | 1 |
| Borucki, D | 1 |
| Detzer, C | 1 |
| Zeiner, KN | 1 |
| Schaumburg, D | 1 |
| Buehring, B | 1 |
| Buttgereit, F | 1 |
| Armbrecht, G | 1 |
| Go, SI | 4 |
| Kim, HG | 4 |
| Kang, MH | 4 |
| Park, S | 2 |
| Lee, GW | 4 |
| Iltar, U | 1 |
| Sözel, H | 1 |
| Sözel, YK | 1 |
| Ataş, Ü | 1 |
| Yücel, OK | 1 |
| Salim, O | 1 |
| Aydin, F | 1 |
| Undar, L | 1 |
| Park, MJ | 2 |
| Song, HN | 2 |
| Kang, JH | 1 |
| Kim, HR | 2 |
| Lanic, H | 1 |
| Kraut-Tauzia, J | 1 |
| Modzelewski, R | 1 |
| Clatot, F | 1 |
| Mareschal, S | 1 |
| Picquenot, JM | 1 |
| Stamatoullas, A | 1 |
| Leprêtre, S | 1 |
| Tilly, H | 1 |
| Jardin, F | 1 |
| Nakamura, N | 1 |
| Hara, T | 1 |
| Shibata, Y | 1 |
| Matsumoto, T | 1 |
| Nakamura, H | 1 |
| Ninomiya, S | 1 |
| Kito, Y | 1 |
| Kitagawa, J | 1 |
| Kanemura, N | 1 |
| Goto, N | 1 |
| Shiraki, M | 1 |
| Miyazaki, T | 1 |
| Takeuchi, T | 1 |
| Shimizu, M | 1 |
| Tsurumi, H | 1 |
| Lee, HR | 1 |
| Kim, Y | 1 |
| Kim, RB | 1 |
| Lee, SI | 1 |
| Xiao, DY | 2 |
| Luo, S | 2 |
| O'Brian, K | 2 |
| Ganti, A | 2 |
| Riedell, P | 2 |
| Sanfilippo, KM | 2 |
| Lynch, RC | 2 |
| Liu, W | 2 |
| Carson, KR | 2 |
| Kahl, BS | 1 |
| Cashen, AF | 1 |
| Fehniger, TA | 1 |
2 trials available for prednisone and Sarcopenia
| Article | Year |
|---|---|
Clinical impact of prognostic nutritional index in diffuse large B cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2019 |
Sarcopenia is an independent prognostic factor in male patients with diffuse large B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2015 |
8 other studies available for prednisone and Sarcopenia
| Article | Year |
|---|---|
Prevalence of sarcopenia in patients with rheumatoid arthritis using the revised EWGSOP2 and the FNIH definition.
Topics: Aged; Arthritis, Rheumatoid; C-Reactive Protein; Cross-Sectional Studies; Glucocorticoids; Humans; N | 2022 |
Prognostic model based on the geriatric nutritional risk index and sarcopenia in patients with diffuse large B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Do | 2020 |
Prognostic impact of the psoas muscle index, a parameter of sarcopenia, in patients with diffuse large B-cell lymphoma treated with rituximab-based chemoimmunotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Lar | 2021 |
A comparison of pectoralis versus lumbar skeletal muscle indices for defining sarcopenia in diffuse large B-cell lymphoma - two are better than one.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2017 |
Sarcopenia is an independent prognostic factor in elderly patients with diffuse large B-cell lymphoma treated with immunochemotherapy.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combine | 2014 |
Prognostic impact of sarcopenia in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2016 |
Impact of sarcopenia on treatment tolerance in United States veterans with diffuse large B-cell lymphoma treated with CHOP-based chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Hospitalization | 2016 |
Longitudinal Body Composition Changes in Diffuse Large B-cell Lymphoma Survivors: A Retrospective Cohort Study of United States Veterans.
Topics: Abdominal Fat; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Pr | 2016 |